Bachem raises $116 million through capital increase
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
Subscribe To Our Newsletter & Stay Updated